#####
Currently, there are 164.91M common shares owned by the public and among those 124.79M shares have been available to trade.
#####
#####
#####
The company’s stock has a 5-day price change of 26.58% and 114.83% over the past three months. ALAB shares are trading 118.52% year to date (YTD), with the 12-month market performance down to -11.73% lower. It has a 12-month low price of $36.22 and touched a high of $147.39 over the same period. ALAB has an average intraday trading volume of 4.54 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 22.26%, 25.27%, and 30.91% respectively.
Institutional ownership of Astera Labs Inc (NASDAQ: ALAB) shares accounts for 60.55% of the company’s 164.91M shares outstanding.
It has a market capitalization of $19.28B and a beta (3y monthly) value of 1.25. The stock’s trailing 12-month PE ratio is 498.34, while the earnings-per-share (ttm) stands at $0.23. The company has a PEG of 11.68 and a Quick Ratio of 13.26 with the debt-to-equity ratio at 0.00. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.68% over the week and 6.90% over the month.
Analysts forecast that Astera Labs Inc (ALAB) will achieve an EPS of 0.32 for the current quarter, 0.34 for the next quarter and 1.72 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.32 while analysts give the company a high EPS estimate of 0.32. Comparatively, EPS for the current quarter was 0.13 a year ago. Earnings per share for the fiscal year are expected to increase by 60.69%, and 27.77% over the next financial year.
#####
Looking at the support for the ALAB, a number of firms have released research notes about the stock. Northland Capital stated their Market Perform rating for the stock in a research note on July 22, 2025, with the firm’s price target at $120. Susquehanna was of a view on May 16, 2025 that the stock is Neutral, while Morgan Stanley gave the stock Overweight rating on May 12, 2025, issuing a price target of $99. Raymond James on their part issued Outperform rating on March 14, 2025.
